Skip to main content

Grzegorz Nowakowski, MD

Rochester, MN
United States

Mayo Clinic, Rochester

Grzegorz (Greg) Nowakowski, M.D., is a consultant and a Professor of Oncology and Medicine, Division of Hematology at Mayo Clinic in Rochester,Minnesota, where he also serves as the Aggressive B-cell Lymphoma Program Director, the Chairman of Education,and an Advanced Hematology Fellowship Program Director. Dr. Nowakowski received his MD from the Medical University of Warsaw, Poland. He completed his internal medicine residency at Yale University Medical School -Norwalk Hospital, Norwalk, Connecticut and his fellowship in Hematology and Medical Oncology at Mayo Clinic, Rochester, Minnesota. Dr Nowakowski joined the Mayo Clinic Lymphoma Group in 2006 as a Mayo Foundation Scholar.Heis an alumnus of the American Society of Hematology (ASH) Clinical Research Training Institute and American Society of Clinical Oncology (ASCO) Leadership Development Program. Dr. Nowakowski’s research focuses on the molecular classification and biology of lymphoproliferative disorders,new approaches to clinical trial design and novel therapies for lymphoma and hematological disorders. Heis an investigator in University of Iowa/Mayo Clinic Lymphoma Specialized Center of Research Excellence program, where he leads career enhancement program. Dr. Nowakowski has authored over 200 articles and numerous book chapters. Dr.Nowakowski serves as a principal investigator of multiple investigator-initiated and cooperative group clinical trials(ECOG, Alliance) and industry studies and serves and a member of ECOG Lymphoma Core Committee. Dr.Nowakowski also chairs the Lymphoma Committee and Hematological Malignancy Program in the Academic and Community Cancer Research United (ACCRU) network. He currently serves as a vice Chair of ASH Clinical Trial Innovation Subcommittee chair of ASCO Research Community Forum and ASCO Clinical Trial Access and Participation Taskforce. Dr. Nowakowski has served as Voting Member of the Oncology Drugs Advisory Committee (ODAC) to the Food and Drug Administration (FDA).

Program Name(s)
Grzegorz Nowakowski